Keep your eye on GlaxoSmithKline. The UK-based multinational drug-maker represents the future, both as a mass-producer of the vaccines that we pray will finally defeat Covid-19 and as a beacon of the way shareholder capitalism will re-position itself in the post-pandemic era.
GSK last week announced a collaboration with its French rival Sanofi to create a Covid-19 vaccine that it aims to manufacture at the rate of ‘hundreds of millions of doses annually’ by the end of next year.
Comments
Don't miss out
Join the conversation with other Spectator readers. Subscribe to leave a comment.
UNLOCK ACCESSAlready a subscriber? Log in